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Abstract
Background: Green tea is one of the most popular beverages worldwide. This review summarizes
the beneficial effects of green tea on cancer prevention.
Methods: Electronic databases, including PubMed (1966–2008), the Cochrane Library (Issue 1,
2008) and Chinese Biomedical Database (1978–2008) with supplement of relevant websites, were
searched. There was no language restriction. The searches ended at March 2008. We included
randomized and non-randomized clinical trials, epidemiological studies (cohort and case-control)
and a meta-analysis. We excluded case series, case reports, in vitro and animal studies. Outcomes
were measured with estimation of relative risk, hazard or odd ratios, with 95% confidence interval.
Results: Forty-three epidemiological studies, four randomized trials and one meta-analysis were
identified. The overall quality of these studies was evaluated as good or moderate. While some
evidence suggests that green tea has beneficial effects on gastrointestinal cancers, the findings are
not consistent.
Conclusion: Green tea may have beneficial effects on cancer prevention. Further studies such as
large and long term cohort studies and clinical trials are warranted.
Background
Tea is one of the most popular beverages around the
world. Popular in countries such as China and Japan,
green tea accounts for 20% of tea consumption worldwide
[1].
Green tea is derived from Camellia sinensis, an evergreen
shrub of the Theaceae family. Unlike black tea which is
fermented, green tea is produced in a non-fermented
process. Green tea may be consumed in the form of a
brewed beverage or capsular extract. In some countries,
tea is used as dietary supplements. In China the medicinal
use of green tea dated back to 4,700 years ago. Currently,
there is no established recommended dose for green tea
extract. Researchers examined the effects of habitually
green tea drinking on cancer prevention; however, evi-
dence has not been corroborated [2-4].
The main active ingredients of green tea include polyphe-
nolic compounds such as epicatechin (EC), epicatechin-3-
gallate (ECG), epigallocatechin (EGC) and epigallocate-
chin-3-gallate (EGCG), all of which may be responsible
for the anti-carcinogenic and anti-mutagenic activities of
green tea. Other polyphenols in green tea include fla-
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vanols and their glycosides and depsides such as choloro-
genic acid, quinic acids, carotenoids, trigalloylglucose,
lignin, protein, chlorophyll, minerals (aluminum or man-
ganese, depending on the soil content), caffeine and a
very small amount of methylxanthines [5].
Polyphenols in green tea were shown to be powerful anti-
oxidants with anti-carcinogenic properties [6]. Human
studies on pharmacokinetics of polyphenols in green tea
were conducted [7,8]. The evidence suggests that ingested
polyphenols and their metabolites play a role in the
action against gastrointestinal cancers.
Many  in vitro and  in vivo studies demonstrated that
polyphenols from green tea were anti-carcinogenic by
inducing apoptosis and inhibiting cell-growth, cyclin-
dependent kinase inhibitor and urokinase (an enzyme
crucial for cancer growth) [1]. Probable action mecha-
nisms include antioxidant and free-radical scavenging
activity and stimulation of detoxification systems through
selective induction or modification of phase I and II met-
abolic enzymes.
In light of growing research findings on green tea, we con-
ducted a systematic review of randomized clinical trials
and epidemiological studies to summarize the current evi-
dence of its beneficial and harmful effects on cancer pre-
vention in humans.
Methods
Databases and search strategy
We searched various electronic databases, including
PubMed (1966–2008) [9], the Cochrane Library (Issue 1,
2008; CD-ROM), Chinese Biomedical Database (CD-
ROM, 1978–2008). No language restriction was applied.
The searches ended at March 2008. The search terms used
included cancer, neoplasm, green tea, tea, Camellia sinen-
sis, diet therapy, case-control study, cohort study, clinical
trial, review, systematic review and meta-analysis. We also
searched the following websites to identify eligible stud-
ies: NCCAM [10], the Cancer Society [11], Complemen-
tary/Integrative Medicine Education Resources (CIMER)
[12], NCI Cancer Information Summaries: Complemen-
tary and Alternative Medicine [13] and the Memorial
Sloan-Kettering Cancer Center [14].
Quality assessment
As various study designs (i.e. randomized, non-rand-
omized, prospective cohort and case-control) are
included in this review, categorization after quality assess-
ment was applied to each study [15] as follows.
Category A (good)
Studies in category A have the least biases and their results
are considered valid. These studies are likely to consist of
(1) clear description of the population, setting, interven-
tions and comparison groups; (2) appropriate measure-
ment of outcomes; (3) appropriate statistical and
analytical methods; (4) no reporting errors; (5) less than
20 percent dropouts; (6) clear reporting of dropouts; and
(7) appropriate consideration and adjustment for poten-
tial confounders.
Category B (fair)
Studies in category B are susceptible to some degrees of
biases that are not sufficient to invalidate the results.
These studies may have sub-optimal adjustments for
potential confounders and may also lack certain informa-
tion that is needed to assess limitations and potential
problems.
Category C (poor)
Studies in category C have significant biases which may
invalidate the results. These studies either do not consider
potential confounders or do not make adjustments for
them appropriately. These studies may have critical flaw
in design, analysis and/or reporting, missing information
and/or discrepancies in reporting.
Inclusion criteria
We included randomized controlled trials, controlled
clinical trials or observational studies including prospec-
tive cohort and case-control studies on cancer prevention
of green tea oral consumption in healthy individuals or
cancer patients. Systematic reviews or meta-analyses were
also included. In this review, only studies in the above
mentioned categories A and B were included.
Exclusion criteria
We excluded case series, case reports, in vitro cell culture
and animal studies. Poor quality studies (i.e. those in Cat-
egory C) were also excluded.
Data abstraction and analysis
Relative risk (RR) or hazard ratio (HR) was used for clini-
cal trials or cohort studies, while odds ratio (OR) was used
for case-control studies. The above effect estimation was
presented with 95% confidence interval (95% CI).
Due to the heterogeneity of study designs, settings, inter-
ventions and outcomes, we did not conduct a meta-anal-
ysis.
Results
A Cochrane systematic review on green tea for cancer
(protocol stage) published in 2004 does not include any
studies [16]. This review identified 48 clinical studies
investigating the consumption of green tea and its associ-
ation with the risk of developing cancer, including 42 epi-
demiological studies [17-58], one phase I trial [59], fourChinese Medicine 2008, 3:12 http://www.cmjournal.org/content/3/1/12
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randomized trials [60-63] and one meta-analysis [64]
(Additional file 1). Twenty-two and 20 of the 42 epidemi-
ological studies were cohort studies and case-control stud-
ies respectively, among which two studies [26,43]
reported data from four cohort studies and one cohort
study [17,18] and one case-control study [41,42] were
reported twice. All studies were published between 1984
and 2008; 44 studies were published in international
journals, three in Chinese [28,32,56] and one in Japanese
[38].
Participants in the included studies ranged from healthy
individuals, pre-cancer patients to cancer patients. Several
studies reported various cancers in their cases or cohorts,
but in this review these data were presented separately in
relevant categories. Average sample size for cohort studies
was 31,798 (from 52 to 102,137 per study), 1,099 for
case-control studies (from 213 to 3,818 per study) and
182 for randomized trials (from 60 to 400 per trial).
Decaffeinated green tea, tea polyphenols (500 mg or 1000
mg) or catechins was used for 3–12 months in rand-
omized trials, whereas regular drinking tea was used for a
fixed period or lifelong time in epidemiological studies.
The outcomes reported from randomized trials included
8-hydroxydeoxyguanosine (8-OHdG) in urine (an indica-
tor for oxidative DNA damage) [60,62], histopathological
examination [61] and incidence of cancer [63]. Risk of
cancer development was the main outcome for epidemio-
logical studies; a few studies reported mortality [20,23],
recurrence [47,49], survival of cancer [57] and sister chro-
matid exchange (SCE) rates [21].
Four randomized trials were placebo-controlled, double-
blinded (three) and of acceptable methodological quality
in terms of randomization, blinding and reporting of the
studies. According to the generic quality grading for all
included studies, 29 studies (60%) were evaluated as
good (A) and the remaining as fair (B).
Cancer prevention
Caner in general (5 studies)
A cohort study of 8,552 people with nine years of follow-
up showed a negative association of green tea consump-
tion with cancer incidence, especially among Japanese
women drinking more than ten cups a day (RR 0.59; 95%
CI, 0.35–0.98) [17,18]. However, a larger cohort study
with 38,540 people in Japan did not show an association
between green tea consumption and sum incidence of all
cancers (RR 1.0; 95% CI, 0.91–1.1 for those drinking two
to four times per day; RR 0.98; 95%CI, 0.88–1.1 for those
drinking five times or more per day, both compared with
those drinking one time or less per day) [19]. Another
large cohort study found no significant benefit in terms of
cancer mortality among a total of 1,134 cancer patients
who consumed green tea and those who did not [20]. A
randomized trial comparing green tea, black tea with
water in 143 heavy smokers found significant decrease in
8-OHdG levels after a 4-month intervention [60]. A pro-
spective cohort study in 52 male smokers demonstrated
that drinking green tea inhibited cigarette-induced
increase in sister chromatid exchange rates [21].
Oral and esophageal cancer (8 studies)
A prospective cohort study followed 20,550 men and
29,671 women for an average of 10.3 years and estimated
the HRs (95% CI) in oral cancer [22]. For women, the HRs
(95% CI) were 0.51 (0.10–2.68), 0.60 (0.17–2.10) and
0.31 (0.09–1.07) for green tea consumption of one to
two, three to four and five or more cups per day respec-
tively, compared with those who drank less than one cup
per day (P  for trend, 0.08). For men, no trend was
observed.
Inconsistent findings exist in case-control and cohort
studies on green tea drinking and esophageal cancer [23-
28]. Two population-based case-control studies of 3,049
subjects found a protective effect of green tea drinking
against esophageal cancer among women [24,25], while
another case-control study of 1,043 subjects showed 39%
decrease of risk of esophageal cancer among alcoholic
drinkers and 31% decrease among smokers [28]. The tea
polyphenol epigallocatechin in urine was inversely associ-
ated with cancer risk when the data of gastric and esopha-
geal cancer sub-sites were combined [27], indicating
protective effect of green tea. However, in terms of death,
a retrospective cohort and a pooled analysis of two cohort
studies with a total of 26,723 subjects demonstrated a
positive association (HR 1.67; 95% CI, 0.89–3.16) (P for
trend, 0.04) of drinking green tea and mortality of
esophageal cancer among men [23,26]. A randomized
controlled trial with 400 participants who were patholog-
ically confirmed to have esophageal precancerous lesions
did not show benefit of decaffeinated green tea for allevi-
ating precancerous lesions or abnormal cell proliferation
compared with calcium as placebo [61].
Stomach cancer (11 studies)
Seven epidemiological studies (one cohort and six case-
control studies) with a total number of 77,777 subjects
showed inverse association of green tea consumption
(urine polyphenol epigallocatechin in one study) and the
risk reduction of stomach cancer [27,28,30,32,34,36,37].
The cohort study with 72,943 subjects showed benefit for
women who consumed five or more cups of green tea per
day (RR 0.51; 95% CI, 0.30–0.86) compared with one cup
per day [30]. However, four studies including two cohort
studies with 102,179 subjects did not show an inverse
association of green tea consumption and risk reduction
of stomach cancer or cancer-caused death [29,30,33,35].Chinese Medicine 2008, 3:12 http://www.cmjournal.org/content/3/1/12
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Pancreatic cancer (4 studies)
Two case-control studies (in three publications) with 522
pancreatic cancer patients and 1,694 controls showed an
inverse association of drinking green tea and the risk of
pancreatic cancer [38,41,42]. By contrast, a hospital-based
case-control study of 124 patients and 124 controls dem-
onstrated a positive association of drinking five cups or
more green tea per day and pancreatic cancer [39]. A pop-
ulation-based cohort study involving 102,137 partici-
pants with 11 years of follow-up did not find any
association of the risk of pancreatic cancer and drinking
green tea [40].
Liver cancer (2 studies)
A population-based case-control study involving 204
patients and 415 controls reported that drinking green tea
reduced the risk of liver cancer by 78% (OR 0.25; 95% CI,
0.11–0.57) among alcoholic drinkers and by 43% among
smokers [28]. A randomized, double-blinded, placebo-
controlled trial in 124 individuals with sero-positive
HBsAg and aflatoxin-albumin adducts showed a signifi-
cant decrease of 8-hydroxydeoxyguanosine after three
months of green tea polyphenols intake [62].
Biliary ducts cancer (1 study)
Statistical analysis showed that green tea consumption
was positively associated with the mortality of biliary duct
cancer in a retrospective cohort study (P ≤ 0.01) [23].
Colorectal cancer (6 studies)
Two case-control studies (in three publications) involving
2,036 patients with colorectal cancer and 2,130 controls
found that drinking green tea reduced the risk of colorec-
tal cancer [41,42,44]. Gender difference was observed in
two cohort studies [45,46]. A prospective cohort study
that followed over 60,000 subjects for an average of 8.9
years found no statistically significant difference between
green tea drinkers and non-drinkers (RR 1.12; 95% CI,
0.97–1.29) [45]. Another cohort study with six years of
follow-up on 69,710 women found significant dose-
response relationship (RR 0.63; 95% CI, 0.45–0.88)
between regular and non-regular green tea drinkers [46].
By contrast, a pooled analysis from two cohort studies on
over 60,000 subjects showed no association between
drinking green tea and a lower risk of colorectal cancer
[43].
Breast cancer (5 studies)
In a meta-analysis of two prospective cohorts of 35,004
Japanese women [64], green tea intake was not associated
with a lower risk of breast cancer (222 cases); and the mul-
tivariate RR for women drinking more than five cups of
green tea was 0.84 (95% CI, -0.57–1.24; P = 0.69) com-
pared with those drinking less than one cup per day. One
case-control study showed significantly reduced risk of
breast cancer by regular drinking a large amount of green
tea [50]. However, a cohort study did not find an associa-
tion of green tea intake with lower risk of breast cancer
[48]. Another two cohort studies showed reduced recur-
rence of breast cancer among patients at stage I and II with
high consumption of green tea (more than three cups per
day) [47,49].
Lung cancer (4 studies)
A randomized trial compared green tea and black tea with
water in 143 heavy smokers for 4 months [60]. The con-
tent of 8-OHdG in urine was reduced among the subjects
in green tea group, but not in black tea or water groups. A
cohort study of 52 male adults, found that green tea drink-
ing blocked cigarette-induced increase in sister chromatid
exchange rates, suggesting potential protection against
lung cancer [21]. Consumption of green tea was found to
be associated with a reduced risk of lung cancer among
non-smoking women in one case-control study [51]. A
phase I dose finding study showed the maximum toler-
ated dose of green tea extract as 3 g/m2 per day in patients
with advanced lung cancer. The dose-limiting toxicities
were diarrhea, nausea and hypertension [59].
Prostate cancer (4 studies)
A double-blind, placebo-controlled trial testing green tea
catechins (600 mg per day for one year) significantly
reduced the incidence of prostate cancer in a group of 60
volunteers with high-grade prostate intraepithelial neo-
plasia; no significant adverse effect was reported [63]. A
case-control study found prostate cancer risk declined
with increasing frequency, duration and quantity of green
tea consumption [53]. A cohort study in 19,561 Japanese
men showed that green tea intake was not associated with
a lower risk of prostate cancer (HR 0.85; 95% CI, 0.50–
1.43) between men drinking five or more cups and less
than one cup per day [54]. However, another recent
cohort study with a larger sample size (n = 49,920) in
Japan suggested that green tea was associated with a
decreased risk of advanced prostate cancer (RR 0.52; 95%
CI, 0.28–0.96) in men drinking five or more cups com-
pared with those drinking less than one cup per day [55].
Urinary bladder cancer (1 study and 1 ongoing trial)
The risk of urinary bladder cancer was significantly
reduced in women who consumed matcha (a powdered
green tea) in a case-control study (n = 882) [52]. A phase
II randomized, double-blind, placebo-controlled, multi-
center trial (n = 330) is currently carried out in the United
States [65].
Endometrial cancer (1 study)
A population-based case-control study (n = 2082) sug-
gested that regular green tea drinking reduced the risk ofChinese Medicine 2008, 3:12 http://www.cmjournal.org/content/3/1/12
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endometrial cancer (OR 0.74; 95% CI, 0.54–1.01) in pre-
menopausal women [56].
Ovarian cancer (1 study)
A cohort study (n = 254) suggested that increasing the
post-diagnosis consumption of green tea may boost the
survival of patients of epithelial ovarian cancer [57].
Adult leukemia (1 study)
A case-control study (n = 217) demonstrated statistical
association (OR 0.51; 95% CI 0.27–0.96) between higher
intake of green tea and reduced risk of adult leukemia in
a dose-response manner [58].
Safety of green tea
Green tea, as a popularly consumed beverage, is relatively
non-toxic [66]. Phase I trial in 17 patients with advanced
lung cancer showed that the maximum tolerated dose of
green tea extract was 3 g/m2 per day [59]. No severe
adverse effects have been reported in association with the
medicinal use of green tea [67]. Consumption of high
doses of green tea or green tea extract (i.e. 5–6 litters per
day) may cause nausea, vomiting, abdominal bloating/
pain, dyspepsia, flatulence and diarrhea [59,67]. Excessive
consumption of caffeine from green tea may also cause
central nervous system stimulation such as dizziness,
insomnia, tremors, restlessness, confusion, diuresis (i.e.
increasing urine output), heart rate irregularities and psy-
chomotor agitation [67].
Human studies did not show severe adverse effects among
volunteers who took 15 tablets of green tea per day (i.e.
2.25 g green tea extracts, 337.5 mg EGCG and 135 mg caf-
feine) for 6 months [68,69]. A randomized, placebo-con-
trolled trial (n = 40) found no adverse effect in healthy
individuals who took green tea polyphenols in the
amount equivalent to the EGCG content in 8–16 cups of
green tea once a day or twice a day in divided doses for
four weeks [69].
Discussion
Current research findings are not sufficient to validate the
effects of green tea on cancer prevention as most evidence
coming from cohort (grade III) and case-control studies
(grade IV) is not consistent. As tea drinking is common in
many populations, it is difficult to randomize subjects
into drinking groups or non-drinking groups. For the
same reason, epidemiological studies are still important
in this field.
This review of randomized trials and epidemiological
studies shows the current evidence in green tea and cancer
prevention. More than half of the studies (58%) suggest
that long-term consumption of green tea may reduce the
risk of certain types of cancer, in particular gastrointestinal
cancers, such as esophageal, stomach, pancreatic, liver
and colorectal cancer. Stratified analysis suggests that
women benefit more than men from green tea drinking.
However, the beneficial effects are not consistent across
all studies. The interpretation of these findings is a chal-
lenge due to the significantly heterogeneous study
designs, settings, populations, exposures, comparisons,
outcome measures and potential publication biases. The
heterogeneity hinders meaningful meta-analysis despite
the large number of studies covered in this systematic
review. The discrepancies in the findings may be due to
the following factors: (1) participants in terms of health
status, family history of cancer, age, gender, ethnic and
other lifestyle confounders such as smoking or alcohol
drinking; (2) definitions of green tea consumption, e.g.
frequency, duration, quantity of green tea and the quality
of green tea products; and (3) study designs and trial set-
tings.
This review shows that the overall evidence for protective
effects of green tea against cancer is inconclusive. There-
fore, further prospective cohort studies and clinical trials
are warranted. Adequate sample size, better descriptions
of populations and/or clear definitions of green tea con-
sumption may be required for conclusive studies.
Moderate consumption of green tea (3–9 cups per day) is
generally safe. People with known allergy/hypersensitivity
to caffeine or tannin should avoid green tea. In general,
the stimulatory effect of green tea is considerably less than
that of coffee [66]. However, pregnant women, nursing
mothers and patients with cardiac conditions are advised
to avoid or limit their intake of green tea to two cups per
day [68].
Conclusion
Great efforts have been made to show the beneficial
effects of green tea consumption on various cancers. Some
epidemiological studies demonstrated protective effects
of green tea consumption on gastrointestinal, breast, lung
and prostate cancer. However, these findings have not
been confirmed by other studies covered in this review.
Future prospective studies are therefore warranted.
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